Cervarix FDA Approval History
FDA Approved: Yes (Discontinued) (First approved October 16, 2009)
Brand name: Cervarix
Generic name: human papillomavirus bivalent (types 16 and 18) vaccine, recombinant
Dosage form: Injection
Company: GlaxoSmithKline
Treatment for: Human Papillomavirus Prophylaxis
Marketing Status: Discontinued
Cervarix (human papillomavirus bivalent (types 16 and 18) is a is a preventative cervical cancer vaccine for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 in girls and young women (aged 10-25).
Development timeline for Cervarix
See also
Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant) Consumer information
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.